2017 ASCO GU Public

Emma Hall, PhD, Clinical Trials and Statistics Unit, The Institute of Cancer Research, presenting Abstract #280, "BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer"

Orlando, FL - 2017 Genitourinary Cancers Symposium - Emma Hall, PhD, Clinical Trials and Statistics Unit, The Institute of Cancer Research, presenting Abstract #280, "BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer," during Oral Abstract Session B: Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers at the 2017 Genitourinary Cancers Symposium in Orlando, Florida, here today, Friday, February 17, 2017. The conference is the premier meeting on the science and treatment of Genitourinary Cancers from basic research to patient-based studies to larger clinical trials and population analyses in the United States. More than 3,000 experts from around the world are attending the meeting which is sponsored by the American Society of Clinical Oncology, the American Society of Radiation Oncology, and the Society of Urologic Oncology. Photo by © ASCO/Todd Buchanan 2017